Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease

Inclusion Criteria: * Any subject with coexisting kidney disease and type 1 or type 2 diabetes is eligible for the study, including: newly-diagnosed subjects, insulin naïve and subjects who have received insulin or an insulin analogue before * Subjects with kidney disease (stage I-IV) including transplant patients will be eligible for the study, if initiated with NovoRapid™" Exclusion Criteria: * Subjects who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit * Subjects with stage V of chronic kidney disease * Subjects who previously enrolled in this study * Known or suspected allergy to trial product(s) or related products